Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2012-02-01

FDA Approved: SAMSCA — Supplemental Application (Otsuka America Pharmaceutical, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SAMSCA (tolvaptan) to update the labeling, including changes to indications or safety information.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Samsca (tolvaptan)

Snippet

SUPPL AP for SAMSCA (TOLVAPTAN)